Mechanisms of action of rapamycin in gliomas
Open Access
- 1 January 2005
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 7 (1) , 1-11
- https://doi.org/10.1215/s1152851704000420
Abstract
Rapamycin has previously been shown to be efficacious against intracerebral glioma xenografts and to act in a cytostatic manner against gliomas. HoweKeywords
This publication has 20 references indexed in Scilit:
- Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.2002
- Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of RapamycinMolecular and Cellular Biology, 2002
- Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategiesNeuro-Oncology, 2002
- Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling PathwayJournal of Biological Chemistry, 2002
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 2002
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTORProceedings of the National Academy of Sciences, 2001
- HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis.2001
- Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors.2000
- The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cellsBritish Journal of Cancer, 2000
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997